Amexdrug Corporation
Amexdrug Corporation (AXRX) Revenue
Annual & quarterly revenue history · segment & region breakdown
AXRX · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsAmexdrug Corporation trailing twelve-month (TTM) revenue is $0.00B, a decrease of 14.61% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2015 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | -$0.00B | -14.61% |
| 2024-12-31 | $0.00B | -$0.00B | -13.20% |
| 2023-12-31 | $0.00B | -$0.00B | -18.81% |
| 2021-12-31 | $0.00B | -$0.00B | -24.25% |
| 2020-12-31 | $0.01B | -$0.00B | -17.55% |
| 2019-12-31 | $0.01B | -$0.00B | -26.52% |
| 2018-12-31 | $0.01B | +$0.00B | +0.76% |
| 2017-12-31 | $0.01B | +$0.00B | +12.10% |
| 2016-12-31 | $0.01B | +$0.00B | +5.07% |
| 2015-12-31 | $0.01B | — | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Amexdrug Corporation receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Amexdrug Corporation reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Amexdrug Corporation's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
AXRX revenue · 4 questionsAXRX's trailing twelve-month (TTM) revenue is $0.00B. That is a decrease of 14.61% year-over-year from $0.00B in FY2025.
▸ Source: FMP · Amexdrug Corporation SEC filings · GAAP · Amexdrug Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026